Literature DB >> 29760046

Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas.

Sharmistha Pal1, David Kozono1, Xiaodong Yang2, Wojciech Fendler1,3, Whitney Fitts4, Jing Ni5, John A Alberta5, Jean Zhao5,6, Kevin X Liu1, Jie Bian1, Nathalene Truffaux7, William A Weiss2,7,8, Adam C Resnick9, Pratiti Bandopadhayay10, Keith L Ligon11, Steven G DuBois12, Sabine Mueller2,7,8, Dipanjan Chowdhury13, Daphne A Haas-Kogan14.   

Abstract

Aberrant chromatin remodeling and activation of the PI3K pathway have been identified as important mediators of pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine glioma (DIPG) pathogenesis. As inhibition of these pathways are promising therapeutic avenues and radiation is the only modality to prolong survival of patients with DIPG, we sought to explore radiosensitizing functions of such inhibition and to explore mechanisms of action of such agents. Here, we demonstrate that combined treatment with radiotherapy and CUDC-907, a novel first-in-class dual inhibitor of histone deacetylases (HDAC) and PI3K, evokes a potent cytotoxic response in pHGG and DIPG models. CUDC-907 modulated DNA damage response by inhibiting radiation-induced DNA repair pathways including homologous recombination and nonhomologous end joining. The radiosensitizing effects of CUDC-907 were mediated by decreased NFκB/Forkhead box M1 (FOXM1) recruitment to promoters of genes involved in the DNA damage response; exogenous expression of NFκB/FOXM1 protected from CUDC-907-induced cytotoxicity. Together, these findings reveal CUDC-907 as a novel radiosensitizer with potent antitumor activity in pHGG and DIPG and provide a preclinical rationale for the combination of CUDC-907 with radiotherapy as a novel therapeutic strategy against pHGG and DIPG. More globally, we have identified NFκB and FOXM1 and their downstream transcriptional elements as critical targets for new treatments for pHGG and DIPG.Significance: These findings describe the radiosensitizing effect of a novel agent in pediatric high-grade gliomas, addressing a critical unmet need of increasing the radiation sensitivity of these highly aggressive tumors. Cancer Res; 78(14); 4007-21. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29760046      PMCID: PMC6294442          DOI: 10.1158/0008-5472.CAN-17-3691

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.

Authors:  Yun Dai; Mohamed Rahmani; Paul Dent; Steven Grant
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

Review 2.  Nuclear factor-kappaB in cancer development and progression.

Authors:  Michael Karin
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

3.  c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer.

Authors:  Angela Nebbioso; Vincenzo Carafa; Mariarosaria Conte; Francesco Paolo Tambaro; Ciro Abbondanza; Joost Martens; Matthias Nees; Rosaria Benedetti; Isabella Pallavicini; Saverio Minucci; Guillermo Garcia-Manero; Francesco Iovino; Gabriella Lania; Concetta Ingenito; Valeria Belsito Petrizzi; Hendrik G Stunnenberg; Lucia Altucci
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

4.  Radiosensitization by inhibition of IkappaB-alpha phosphorylation in human glioma cells.

Authors:  Gui-Rong Ding; Naoko Honda; Takehisa Nakahara; Furong Tian; Masami Yoshida; Hideki Hirose; Junji Miyakoshi
Journal:  Radiat Res       Date:  2003-08       Impact factor: 2.841

5.  p21 is necessary for the p53-mediated G1 arrest in human cancer cells.

Authors:  T Waldman; K W Kinzler; B Vogelstein
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

6.  Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of p300/CBP coactivators.

Authors:  Michael L Major; Rita Lepe; Robert H Costa
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

7.  Trichostatin A potentiates TRAIL-induced antitumor effects via inhibition of ERK/FOXM1 pathway in gastric cancer.

Authors:  Lin Li; Biao Fan; Lian-Hai Zhang; Xiao-Fang Xing; Xiao-Jing Cheng; Xiao-Hong Wang; Ting Guo; Hong Du; Xian-Zi Wen; Jia-Fu Ji
Journal:  Tumour Biol       Date:  2016-02-01

8.  The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma.

Authors:  Gang Wu; Alexander K Diaz; Barbara S Paugh; Sherri L Rankin; Bensheng Ju; Yongjin Li; Xiaoyan Zhu; Chunxu Qu; Xiang Chen; Junyuan Zhang; John Easton; Michael Edmonson; Xiaotu Ma; Charles Lu; Panduka Nagahawatte; Erin Hedlund; Michael Rusch; Stanley Pounds; Tong Lin; Arzu Onar-Thomas; Robert Huether; Richard Kriwacki; Matthew Parker; Pankaj Gupta; Jared Becksfort; Lei Wei; Heather L Mulder; Kristy Boggs; Bhavin Vadodaria; Donald Yergeau; Jake C Russell; Kerri Ochoa; Robert S Fulton; Lucinda L Fulton; Chris Jones; Frederick A Boop; Alberto Broniscer; Cynthia Wetmore; Amar Gajjar; Li Ding; Elaine R Mardis; Richard K Wilson; Michael R Taylor; James R Downing; David W Ellison; Jinghui Zhang; Suzanne J Baker
Journal:  Nat Genet       Date:  2014-04-06       Impact factor: 38.330

9.  Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma.

Authors:  Hamid Nikbakht; Eshini Panditharatna; Leonie G Mikael; Rui Li; Tenzin Gayden; Matthew Osmond; Cheng-Ying Ho; Madhuri Kambhampati; Eugene I Hwang; Damien Faury; Alan Siu; Simon Papillon-Cavanagh; Denise Bechet; Keith L Ligon; Benjamin Ellezam; Wendy J Ingram; Caedyn Stinson; Andrew S Moore; Katherine E Warren; Jason Karamchandani; Roger J Packer; Nada Jabado; Jacek Majewski; Javad Nazarian
Journal:  Nat Commun       Date:  2016-04-06       Impact factor: 14.919

Review 10.  Mutations in chromatin machinery and pediatric high-grade glioma.

Authors:  Rishi R Lulla; Amanda Muhs Saratsis; Rintaro Hashizume
Journal:  Sci Adv       Date:  2016-03-18       Impact factor: 14.136

View more
  28 in total

1.  Sequential Targeting in Crosslinking Nanotheranostics for Tackling the Multibarriers of Brain Tumors.

Authors:  Hao Wu; Hongwei Lu; Wenwu Xiao; Jinfan Yang; Hongxu Du; Yingbin Shen; Haijing Qu; Bei Jia; Suman K Manna; Mythili Ramachandran; Xiangdong Xue; Zhao Ma; Xiaobao Xu; Zhongling Wang; Yixuan He; Kit S Lam; Robert J Zawadzki; Yuanpei Li; Tzu-Yin Lin
Journal:  Adv Mater       Date:  2020-02-20       Impact factor: 30.849

2.  Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).

Authors:  Kristina A Cole; Sharmistha Pal; Rachel A Kudgus; Heba Ijaz; Xiaowei Liu; Charles G Minard; Bruce R Pawel; John M Maris; Daphne A Haas-Kogan; Stephan D Voss; Stacey L Berg; Joel M Reid; Elizabeth Fox; Brenda J Weigel
Journal:  Clin Cancer Res       Date:  2019-12-19       Impact factor: 12.531

Review 3.  Glioblastoma: Current Status, Emerging Targets, and Recent Advances.

Authors:  Amandeep Thakur; Chetna Faujdar; Ram Sharma; Sachin Sharma; Basant Malik; Kunal Nepali; Jing Ping Liou
Journal:  J Med Chem       Date:  2022-07-05       Impact factor: 8.039

Review 4.  Molecular Genetics and Targeted Therapies for Paediatric High-grade Glioma.

Authors:  Kathrine S Rallis; Alan Mathew George; Anna Maria Wozniak; Carola Maria Bigogno; Barbara Chow; John Gerrard Hanrahan; Michail Sideris
Journal:  Cancer Genomics Proteomics       Date:  2022 Jul-Aug       Impact factor: 3.395

5.  A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma.

Authors:  Sharmistha Pal; Jakub P Kaplan; Huy Nguyen; Sylwia A Stopka; Milan R Savani; Michael S Regan; Quang-De Nguyen; Kristen L Jones; Lisa A Moreau; Jingyu Peng; Marina G Dipiazza; Andrew J Perciaccante; Xiaoting Zhu; Bradley R Hunsel; Kevin X Liu; Sanda Alexandrescu; Rachid Drissi; Mariella G Filbin; Samuel K McBrayer; Nathalie Y R Agar; Dipanjan Chowdhury; Daphne A Haas-Kogan
Journal:  Cancer Cell       Date:  2022-08-18       Impact factor: 38.585

Review 6.  Mesenchymal Epithelial Transition Factor Signaling in Pediatric Nervous System Tumors: Implications for Malignancy and Cancer Stem Cell Enrichment.

Authors:  Amanda Rose Khater; Tamara Abou-Antoun
Journal:  Front Cell Dev Biol       Date:  2021-05-13

7.  Antagonizing CDK8 Sensitizes Colorectal Cancer to Radiation Through Potentiating the Transcription of e2f1 Target Gene apaf1.

Authors:  Bin Chen; Pengbo Wen; Guanshuo Hu; Yang Gao; Xiaojing Qi; Kaili Zhu; Shaopeng Chen; Lijun Wu; An Xu; Guoping Zhao
Journal:  Front Cell Dev Biol       Date:  2020-06-12

8.  Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells.

Authors:  Seiichi Okabe; Yuko Tanaka; Mitsuru Moriyama; Akihiko Gotoh
Journal:  Cancer Chemother Pharmacol       Date:  2020-01-04       Impact factor: 3.333

Review 9.  Brain stem gliomas and current landscape.

Authors:  Brandon Wummer; Delaney Woodworth; Catherine Flores
Journal:  J Neurooncol       Date:  2021-01-04       Impact factor: 4.130

Review 10.  Radiation in Combination With Targeted Agents and Immunotherapies for Pediatric Central Nervous System Tumors - Progress, Opportunities, and Challenges.

Authors:  Bo Qiu; Cassie Kline; Sabine Mueller
Journal:  Front Oncol       Date:  2021-06-30       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.